Barclays’s TherapeuticsMD TXMD Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q4 | – | Sell |
-44
| Closed | -$47 | – | 5698 |
|
|
2025
Q3 | $47 | Buy |
+44
| New | +$49 | ﹤0.01% | 5315 |
|
|
2024
Q1 | – | Sell |
-63
| Closed | -$142 | – | 5373 |
|
|
2023
Q4 | $142 | Buy |
+63
| New | +$152 | ﹤0.01% | 5162 |
|
|
2022
Q3 | – | Sell |
-4,000
| Closed | -$40K | – | 5143 |
|
|
2022
Q2 | $40K | Buy |
4,000
+2,542
| +174% | +$24.3K | ﹤0.01% | 4129 |
|
|
2022
Q1 | $28K | Sell |
1,458
-8,007
| -85% | -$126K | ﹤0.01% | 4332 |
|
|
2021
Q4 | $168K | Buy |
9,465
+6,225
| +192% | +$187K | ﹤0.01% | 3617 |
|
|
2021
Q3 | $121K | Buy |
+3,240
| New | +$144K | ﹤0.01% | 3833 |
|
|
2021
Q2 | – | Sell |
-6,134
| Closed | -$411K | – | 5086 |
|
|
2021
Q1 | $411K | Buy |
6,134
+4,441
| +262% | +$348K | ﹤0.01% | 3295 |
|
|
2020
Q4 | $103K | Sell |
1,693
-486
| -22% | -$33.2K | ﹤0.01% | 4121 |
|
|
2020
Q3 | $171K | Buy |
2,179
+2,077
| +2,036% | +$166K | ﹤0.01% | 3940 |
|
|
2020
Q2 | $7K | Buy |
102
+101
| +10,100% | +$5.88K | ﹤0.01% | 5367 |
|
|
2020
Q1 | $0 | Sell |
1
-4,679
| -100% | -$464K | ﹤0.01% | 6459 |
|
|
2019
Q4 | $566K | Buy |
4,680
+2,719
| +139% | +$391K | ﹤0.01% | 4191 |
|
|
2019
Q3 | $355K | Buy |
+1,961
| New | +$276K | ﹤0.01% | 4524 |
|
|
2019
Q2 | – | Sell |
-2,480
| Closed | -$604K | – | 7285 |
|
|
2019
Q1 | $604K | Buy |
+2,480
| New | +$656K | ﹤0.01% | 3939 |
|
|
2018
Q4 | – | Sell |
-4
| Closed | -$1K | – | 7338 |
|
|
2018
Q3 | $1K | Buy |
+4
| New | +$1.23K | ﹤0.01% | 7041 |
|
|
2018
Q2 | – | Sell |
-746
| Closed | -$228K | – | 7294 |
|
|
2018
Q1 | $182K | Buy |
746
+744
| +37,200% | +$209K | ﹤0.01% | 4914 |
|
|
2017
Q4 | $1K | Sell |
2
-70
| -97% | -$19.5K | ﹤0.01% | 6866 |
|
|
2017
Q3 | $19K | Buy |
72
+45
| +167% | +$13K | ﹤0.01% | 5824 |
|
|
2017
Q2 | $8K | Sell |
27
-349
| -93% | -$87.4K | ﹤0.01% | 6122 |
|
|
2017
Q1 | $135K | Buy |
376
+329
| +700% | +$102K | ﹤0.01% | 4661 |
|
|
2016
Q4 | $14K | Sell |
47
-339
| -88% | -$105K | ﹤0.01% | 5782 |
|
|
2016
Q3 | $132K | Buy |
386
+384
| +19,200% | +$140K | ﹤0.01% | 4307 |
|
|
2016
Q2 | $1K | Hold |
2
| – | – | ﹤0.01% | 6170 |
|
|
2016
Q1 | $1K | Sell |
2
-1,394
| -100% | -$476K | ﹤0.01% | 6009 |
|
|
2015
Q4 | $698K | Buy |
1,396
+1,383
| +10,638% | +$511K | ﹤0.01% | 2932 |
|
|
2015
Q3 | $3K | Sell |
13
-36
| -73% | -$12.8K | ﹤0.01% | 6239 |
|
|
2015
Q2 | $17K | Sell |
49
-22
| -31% | -$7.76K | ﹤0.01% | 5786 |
|
|
2015
Q1 | $21K | Sell |
71
-52
| -42% | -$12.7K | ﹤0.01% | 5806 |
|
|
2014
Q4 | $25K | Buy |
123
+52
| +73% | +$10.7K | ﹤0.01% | 6197 |
|
|
2014
Q3 | $14K | Buy |
71
+37
| +109% | +$9.32K | ﹤0.01% | 6705 |
|
|
2014
Q2 | $7K | Sell |
34
-251
| -88% | -$55.9K | ﹤0.01% | 7006 |
|
|
2014
Q1 | $85K | Sell |
285
-276
| -49% | -$87.9K | ﹤0.01% | 5585 |
|
|
2013
Q4 | $140K | Buy |
561
+399
| +246% | +$87.4K | ﹤0.01% | 5344 |
|
|
2013
Q3 | $16K | Buy |
162
+80
| +98% | +$9.67K | ﹤0.01% | 6623 |
|
|
2013
Q2 | $12K | Buy |
+82
| New | +$11.2K | ﹤0.01% | 7062 |
|
Other funds holding TXMD
RCMNY
CC
TC
ACM
Barclays's TXMD Position: Q4 2025 in Review
Barclays sold out of TherapeuticsMD (TXMD) in Q4 2025, closing a stake of 44 shares — an estimated $47 sold.
Barclays first reported a position in TXMD in Q2 2013 and held it in 35 quarters. The position peaked at $698K in Q4 2015. 44 funds tracked by Wall St. Rank hold TXMD as of Q4 2025.
- Barclays reported no remaining TherapeuticsMD position as of Q4 2025 after selling out during the quarter.
- Barclays sold 44 TherapeuticsMD shares in Q4 2025, an estimated $47.
- Barclays first reported a position in TherapeuticsMD in Q2 2013 and held it in 35 quarters.
- Barclays's TherapeuticsMD position peaked at $698K in Q4 2015.
- 44 funds tracked by Wall St. Rank held TherapeuticsMD as of Q4 2025.
Based on Barclays's 13F filing for Q4 2025, filed 13 Feb 2026.